how big is Vivanza Biosci.?

As of Jun 06, Vivanza Biosciences Ltd has a market capitalization of 10.00 Cr, with recent net sales of 7.42 Cr and a net profit of -0.67 Cr over the last four quarters. Shareholder's funds are 4.64 Cr, and total assets amount to 19.50 Cr as of Mar'24.

Market Cap: As of Jun 06, Vivanza Biosciences Ltd has a market capitalization of 10.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes data from Mar'25, Dec'24, Sep'24, and Jun'24, is 7.42 Cr. The sum of Net Profit for the same quarters is -0.67 Cr. This data is presented on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: This is also on a Consolidated basis for the latest annual period ending in Mar'24. The Shareholder's Funds are reported at 4.64 Cr, while Total Assets amount to 19.50 Cr.

What does Vivanza Biosci. do?

Vivanza Biosciences Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, focusing on providing quality pharmaceutical products globally. Established in 1982, it reported net sales of 0 Cr and a net profit of -1 Cr for the quarter ending March 2025.

Overview:<BR>Vivanza Biosciences Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company, focusing on providing global quality pharmaceutical products at competitive prices.<BR><BR>History:<BR>Vivanza Biosciences Ltd was established in March 1982 and was initially known as Ivee Injectaa Limited. It transitioned from a Private Limited Company to a Public Limited Company in May 1992. The company rebranded and came into existence as Vivanza Biosciences in April 2016. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -1 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 10 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 32 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 2.15 <BR>Return on Equity: -16.92% <BR>Price to Book: 2.43<BR><BR>Contact Details:<BR>Address: 403 Sarthik 2 Opp Rajpath Club, S G Highway Ahmedabad Gujarat : 380054 <BR>Tel: 91-07405699869 <BR>Website: http://www.vivanzabiosciences.com

Who are in the management team of Vivanza Biosci.?

As of March 2022, the management team of Vivanza Biosci includes Hemant Parikh (Director), Sunil Shah (Independent Director), Avinash G. Bhojwani (Company Secretary & Compliance Officer), Apeksha Vyas (Independent Director), and Jayendra Mehta (Managing Director). Avinash G. Bhojwani is the only member receiving remuneration, amounting to Rs. 4.57 lacs.

As of March 2022, the management team of Vivanza Biosci includes the following individuals:<BR><BR>1. Hemant Parikh - Director<BR>2. Sunil Shah - Independent Director<BR>3. Avinash G. Bhojwani - Company Secretary & Compliance Officer<BR>4. Apeksha Vyas - Independent Director<BR>5. Jayendra Mehta - Managing Director<BR><BR>Avinash G. Bhojwani is the only member of the management team receiving remuneration, which is Rs. 4.57 lacs.

Has Vivanza Biosci. declared dividend?

No Dividend History Available

Who are the peers of the Vivanza Biosci.?

Vivanza Biosci.'s peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Cian Healthcare, Beryl Drugs, Ortin Global, and Adline Chem Lab. While Sun Pharma, Cipla, and Dr Reddy's Labs show excellent management and growth, Vivanza Biosci. has below average performance with a 1-year return of -60.94%.

Peers: The peers of Vivanza Biosci. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Cian Healthcare, Beryl Drugs, Ortin Global, and Adline Chem Lab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and the rest have below average management risk. Growth is excellent at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while below average growth is found at Vivanza Biosci., Divi's Lab., Torrent Pharma, Cian Healthcare, Beryl Drugs, Ortin Global, and Adline Chem Lab. Excellent capital structure is noted at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, whereas below average capital structure is present at Vivanza Biosci., Cian Healthcare, Beryl Drugs, Ortin Global, and Adline Chem Lab.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.96%, while Cian Healthcare has the lowest at -82.59%. Vivanza Biosci.'s 1-year return is -60.94%, which is significantly lower than Divi's Lab. and higher than Cian Healthcare. Additionally, the six-month return is negative for Vivanza Biosci., Cian Healthcare, Beryl Drugs, Ortin Global, and Adline Chem Lab.

Is Vivanza Biosci. overvalued or undervalued?

As of May 13, 2025, Vivanza Biosci. is considered risky and overvalued due to a negative PE ratio of -9.52, an EV to EBIT of -18.05, and a ROE of -16.92%, significantly underperforming compared to its peers, with a 59.33% decline in stock performance over the past year.

As of 13 May 2025, the valuation grade for Vivanza Biosci. has moved from attractive to risky, indicating a significant shift in the company's perceived value. The company is currently considered overvalued, given its negative PE ratio of -9.52 and an EV to EBIT of -18.05, which highlight underlying financial distress. Additionally, the ROE stands at -16.92%, further emphasizing the challenges faced by the company.<BR><BR>In comparison to its peers, Vivanza Biosci. lags significantly behind. For instance, Altius Telecom, rated very attractive, boasts a PE ratio of 52.97, while other peers like Embassy Office REIT and Inventurus Knowledge are categorized as very expensive with PE ratios of 23.06 and 56.63, respectively. The stark contrast in these ratios suggests that Vivanza Biosci. is not only underperforming but also carries a higher risk profile relative to its industry counterparts. Recent stock performance shows a decline of 59.33% over the past year, contrasting sharply with the Sensex's return of 7.65%, reinforcing the notion of overvaluation.

What is the technical trend for Vivanza Biosci.?

As of June 4, 2025, Vivanza Biosci's trend has shifted to mildly bearish, indicated by daily moving averages and weekly RSI, despite a mildly bullish weekly MACD, with overall indicators suggesting weakness and significant underperformance over the past year.

As of 4 June 2025, the technical trend for Vivanza Biosci has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish trend and the weekly RSI showing bearish momentum. Although the weekly MACD is mildly bullish, the overall indicators, including the Bollinger Bands and KST on a monthly basis, suggest weakness. The Dow Theory indicates no clear trend in both weekly and monthly perspectives. The stock has underperformed significantly over the past year, further supporting the bearish outlook.

Who are the top shareholders of the Vivanza Biosci.?

The top shareholders of Vivanza Biosci are Parth Hemant Parikh with 19.77%, Ashoka Metcast Limited with 3.85%, and individual investors who collectively own 73.69%. There are no institutional investors or mutual funds involved.

The top shareholders of Vivanza Biosci include Parth Hemant Parikh, who holds the highest stake at 19.77%. The next significant public shareholder is Ashoka Metcast Limited, with a holding of 3.85%. Additionally, individual investors collectively hold a substantial 73.69% of the company's shares. There are no institutional investors or mutual funds involved in the shareholding.

When is the next results date for Vivanza Biosci.?

Vivanza Biosci. will announce its results on 11 November 2025.

Vivanza Biosci. is scheduled to declare its results on 11 November 2025.

Are Vivanza Biosci. latest results good or bad?

Vivanza Biosciences' latest results show impressive revenue growth of 1,745.33% year-over-year, but concerns arise from a significantly compressed operating margin of 1.08% and a 49.53% decline in stock value over the past year, indicating potential risks for investors.

Vivanza Biosciences' latest results present a mixed picture. On one hand, the company reported a significant increase in revenue, with Q2 FY2026 net sales reaching ₹55.36 crores, marking a remarkable 1,745.33% year-over-year growth. Additionally, net profit rose to ₹0.56 crores, reflecting a staggering 2,700.00% increase compared to the same quarter last year.<BR><BR>However, despite this explosive revenue growth, the company's profitability remains a concern. The operating margin has dramatically compressed to just 1.08%, down from 14.75% in the previous year, indicating that the company is struggling to convert its sales into meaningful profits. The profit after tax (PAT) margin is also very thin at 1.01%, which raises questions about the sustainability of this growth.<BR><BR>Furthermore, the stock has experienced significant volatility, with a 49.53% decline over the past year, suggesting that investor confidence is low. The absence of institutional interest and a substantial reduction in promoter stake further complicate the outlook.<BR><BR>In summary, while the revenue and profit figures show impressive growth, the underlying operational challenges and market performance suggest that the results are not entirely positive. Investors should be cautious, as the thin margins and high volatility indicate potential risks ahead.

How has been the historical performance of Vivanza Biosci.?

Vivanza Biosci. experienced significant financial declines, reporting net sales of 7.42 Cr in March 2025, down from 27.84 Cr in March 2024, resulting in a loss with a profit after tax of -0.67 Cr. The company faced negative cash flow and decreased total assets and liabilities during this period.

Answer:<BR>The historical performance of Vivanza Biosci. shows significant fluctuations in its financial metrics over the years, culminating in a loss in the most recent fiscal year.<BR><BR>Breakdown:<BR>Vivanza Biosci. reported net sales of 7.42 Cr in March 2025, a sharp decline from 27.84 Cr in March 2024 and 17.81 Cr in March 2023. The total operating income mirrored this trend, dropping to 7.42 Cr in March 2025 from 27.84 Cr in the previous year. Total expenditure also decreased to 7.79 Cr in March 2025 from 26.77 Cr in March 2024. Operating profit (PBDIT) turned negative at -0.31 Cr in March 2025, following a profit of 1.12 Cr in March 2024. Consequently, the profit before tax fell to -0.67 Cr in March 2025, down from 0.70 Cr in March 2024, leading to a profit after tax of -0.67 Cr compared to a profit of 0.55 Cr in the prior year. The company's total liabilities decreased to 16.45 Cr in March 2025 from 19.50 Cr in March 2024, while total assets also fell to 16.45 Cr from 19.50 Cr. Cash flow from operating activities was negative at -2.00 Cr in March 2025, contrasting with a positive cash flow of 2.00 Cr in March 2024. Overall, the financial performance indicates a challenging year for Vivanza Biosci., marked by declining revenues and profitability.

Should I buy, sell or hold Vivanza Biosci.?

Which are the latest news on Vivanza Biosci.?

Why is Vivanza Biosci. falling/rising?

As of 16-Dec, Vivanza Biosciences Ltd's stock price is at 2.08, down 0.48%, with significant declines of 40.23% year-to-date and 85.04% over three years, contrasting with a 38.05% gain in the Sensex. The stock is below its moving averages, indicating a bearish trend despite increased investor participation.

As of 16-Dec, Vivanza Biosciences Ltd's stock price is falling, currently at 2.08, reflecting a change of -0.01 or -0.48%. The stock has experienced significant declines over various periods, with a year-to-date drop of 40.23% and a one-year decline of 42.70%. Over the past three years, the stock has plummeted by 85.04%, while the benchmark Sensex has shown a positive return of 38.05% during the same timeframe. <BR><BR>Additionally, the stock is trading below its moving averages across multiple timeframes, indicating a bearish trend. Despite a rise in investor participation, with delivery volume increasing by 215.3% against the 5-day average, the overall performance remains weak. The stock's performance today is described as inline with the sector, but the overall negative returns suggest that the stock is struggling to gain traction in the market.